Adele P Williams1, Jerry E Stewart1, Laura L Stafman1, Jamie M Aye2, Elizabeth Mroczek-Musulman3, Changchun Ren4, Karina Yoon5, Kimberly Whelan2, Elizabeth A Beierle6. 1. University of Alabama at Birmingham, Department of Surgery, Birmingham, AL. 2. University of Alabama at Birmingham, Department of Hematology Oncology, Birmingham, AL. 3. Children's of Alabama, Department of Pathology, Birmingham, AL. 4. University of Alabama at Birmingham, Department of Neonatology, Birmingham, AL. 5. University of Alabama at Birmingham, Department of Pharmacology, Birmingham, AL. 6. University of Alabama at Birmingham, Department of Surgery, Birmingham, AL. Electronic address: Elizabeth.beierle@childrensal.org.
Abstract
BACKGROUND: Patient derived xenografts (PDXs) provide a unique opportunity for investigators to study tumor cell activity, response to therapeutics, and resistance patterns without exposing the human patient to experimental compounds, and thereby play a crucial role in pre-clinical evaluation of new therapies. It has been reported that PDXs may undergo a transformation to lymphoma, most commonly associated with Epstein Barr virus (EBV). If the character of a xenograft becomes compromised and remains undetected, it could have a detrimental impact on the research community as a whole. Our lab has established a number of pediatric solid tumor PDXs which accurately recapitulate the human tumors following several passages. One particular neuroblastoma PDX was noted to grow quickly and with an unusual phenotype, leading us to hypothesize that this PDX had undergone a transformation. METHODS: The PDX in question was investigated with histology, immunohistochemistry (IHC), EBER in situ hybridization, and PCR to determine its identity. RESULTS: Histology on the tumor revealed a small, round blue cell tumor similar to the original neuroblastoma from which it was derived. IHC staining showed that the tumor was composed of lymphocytes that were CD3 positive, <5% CD4 positive, and CD20 negative. The cells were Epstein Barr virus negative. PCR demonstrated that the tumor was human and not murine in origin. CONCLUSION: These findings indicate that a human T Cell lymphoma developed in place of this neuroblastoma PDX. Changes in PDX identity such as this one will significantly impact studies utilizing pediatric PDXs and the mechanism by which this occurred warrants further investigation.
BACKGROUND:Patient derived xenografts (PDXs) provide a unique opportunity for investigators to study tumor cell activity, response to therapeutics, and resistance patterns without exposing the humanpatient to experimental compounds, and thereby play a crucial role in pre-clinical evaluation of new therapies. It has been reported that PDXs may undergo a transformation to lymphoma, most commonly associated with Epstein Barr virus (EBV). If the character of a xenograft becomes compromised and remains undetected, it could have a detrimental impact on the research community as a whole. Our lab has established a number of pediatric solid tumor PDXs which accurately recapitulate the humantumors following several passages. One particular neuroblastoma PDX was noted to grow quickly and with an unusual phenotype, leading us to hypothesize that this PDX had undergone a transformation. METHODS: The PDX in question was investigated with histology, immunohistochemistry (IHC), EBER in situ hybridization, and PCR to determine its identity. RESULTS: Histology on the tumor revealed a small, round blue cell tumor similar to the original neuroblastoma from which it was derived. IHC staining showed that the tumor was composed of lymphocytes that were CD3 positive, <5% CD4 positive, and CD20 negative. The cells were Epstein Barr virus negative. PCR demonstrated that the tumor was human and not murine in origin. CONCLUSION: These findings indicate that a human T Cell lymphoma developed in place of this neuroblastoma PDX. Changes in PDX identity such as this one will significantly impact studies utilizing pediatric PDXs and the mechanism by which this occurred warrants further investigation.
Authors: Christian Wetterauer; Tatjana Vlajnic; Julia Schüler; Joel R Gsponer; George N Thalmann; Marco Cecchini; Julia Schneider; Tobias Zellweger; Heike Pueschel; Alexander Bachmann; Christian Ruiz; Stephan Dirnhofer; Lukas Bubendorf; Cyrill A Rentsch Journal: Prostate Date: 2015-01-13 Impact factor: 4.104
Authors: Gennadiy Bondarenko; Andrey Ugolkov; Stephen Rohan; Piotr Kulesza; Oleksii Dubrovskyi; Demirkan Gursel; Jeremy Mathews; Thomas V O'Halloran; Jian J Wei; Andrew P Mazar Journal: Neoplasia Date: 2015-09 Impact factor: 5.715
Authors: Alberto J Taurozzi; Ramprakash Beekharry; Michelle Wantoch; Marie-Christine Labarthe; Hannah F Walker; Robert I Seed; Matthew Simms; Greta Rodrigues; James Bradford; Geertje van der Horst; Gabri van der Pluijm; Anne T Collins Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240
Authors: Malte von Bonin; Martin Wermke; Kadriye Nehir Cosgun; Christian Thiede; Martin Bornhauser; Gerard Wagemaker; Claudia Waskow Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240
Authors: Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Hooper R Markert; Evan F Garner; Colin H Quinn; Shoeb B Lallani; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle Journal: Sci Rep Date: 2019-09-13 Impact factor: 4.379